Our findings, in conjunction with existing literature, suggest that monitoring IGF-1 levels may offer additional insights into the effectiveness of leptin replacement therapy in managing lipodystrophy and related metabolic complications. This evidence concerns the gene IGF1 and lipodystrophy.